Short Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 14.5%

Immunic, Inc. (NASDAQ:IMUX) saw a large growth in short interest in the month of February. As of February 27th, there was short interest totaling 7,579,660 shares, a growth of 14.5% from the February 12th total of 6,620,441 shares. Based on an average trading volume of 2,846,310 shares, the days-to-cover ratio is currently 2.7 days. Approximately 6.8% of the shares of the company are short sold. Approximately 6.8% of the shares of the company are short sold. Based on an average trading volume of 2,846,310 shares, the days-to-cover ratio is currently 2.7 days.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IMUX shares. Chardan Capital raised shares of Immunic to a “strong-buy” rating in a report on Wednesday, November 19th. D. Boral Capital dropped their price target on shares of Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. HC Wainwright decreased their price objective on shares of Immunic from $8.00 to $5.00 and set a “buy” rating for the company in a report on Monday, March 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. Finally, Brookline Capital Acquisition raised Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $6.00.

Hedge Funds Weigh In On Immunic

A number of institutional investors have recently bought and sold shares of IMUX. Nantahala Capital Management LLC bought a new position in shares of Immunic during the 4th quarter valued at $2,337,000. Vanguard Group Inc. increased its position in Immunic by 5.3% during the third quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after buying an additional 219,957 shares during the last quarter. Laurion Capital Management LP increased its position in Immunic by 106.3% during the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after buying an additional 2,000,000 shares during the last quarter. Millennium Management LLC raised its holdings in Immunic by 544.6% during the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after buying an additional 2,888,829 shares in the last quarter. Finally, Focus Partners Wealth lifted its position in shares of Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after buying an additional 39,063 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

NASDAQ IMUX traded up $0.04 on Tuesday, reaching $1.20. The company’s stock had a trading volume of 2,699,646 shares, compared to its average volume of 3,835,208. Immunic has a twelve month low of $0.51 and a twelve month high of $1.51. The firm’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.78. The stock has a market cap of $156.55 million, a PE ratio of -1.71 and a beta of 1.45.

Immunic (NASDAQ:IMUX) last released its earnings results on Thursday, February 26th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities research analysts anticipate that Immunic will post -0.94 EPS for the current fiscal year.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.